The CHALENSE study demonstrated that a structured exercise program after adjuvant chemotherapy improved disease-free and overall survival in colon cancer patients. The magnitude of this benefit is comparable to that of established chemotherapy drugs like oxaliplatin, making exercise a critical, non-pharmacological standard of care.
The ALASCA trial showed aspirin halves recurrence risk in colorectal cancer patients with PI3K pathway alterations. This finding makes it critical to perform genomic sequencing on all patients, including those with non-metastatic disease, to identify the ~37% who could benefit from this simple, safe intervention.
In patients under surveillance for colorectal cancer, the median time from a positive ctDNA test to radiographic recurrence is extremely short—only 3 to 5 months. This narrow window underscores the high-risk nature of this state and the critical urgency required to enroll these patients into clinical trials immediately upon ctDNA detection.
While the DYNAMIC-2 trial confirmed a ctDNA-guided approach is non-inferior for Stage II colon cancer and reduces chemotherapy use, the DYNAMIC-3 trial in Stage III patients failed to prove non-inferiority for de-escalation or show benefit for escalation. This highlights a critical, stage-dependent limitation in using current MRD assays.
A post-hoc analysis found celecoxib, which showed no overall benefit, nearly doubled 3-year disease-free survival (22% to 41%) specifically in patients who were ctDNA-positive after completing adjuvant therapy. This compelling, hypothesis-generating data suggests a targeted role for a common anti-inflammatory drug in the highest-risk population.
An AJCC expert panel found T-stage (tumor depth) is a more dominant prognostic factor than the traditional N-stage (lymph node involvement). This fundamental shift, likely for the 9th edition, will reclassify many patients, upstaging some stage II and downstaging some stage III patients to create a more accurate, hierarchical system.